Bipartisan Bill Would Let Doctors Administer MDMA and Psilocybin to Seriously Ill Patients
A new bipartisan effort in Congress aims to give dying patients access to psychedelic therapies. The Freedom to Heal Act would allow doctors to legally administer Schedule I drugs like MDMA and psilocybin to patients with life threatening conditions.
New:Â Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
| Key Takeaways | |
|---|---|
| Bill Name | Freedom to Heal Act |
| Sponsors | Sens. Cory Booker (D-NJ) and Rand Paul (R-KY); Reps. Madeleine Dean (D-PA) and Nancy Mace (R-SC) |
| Target Substances | MDMA, psilocybin, and other Schedule I drugs |
| Eligible Patients | Those with life threatening illnesses or severe mental health conditions |
| Mechanism | Amends the Controlled Substances Act to allow DEA registration for physicians |
| FDA Status | Both MDMA and psilocybin hold breakthrough therapy designations |
Do you work in the ketamine industry? Save thousands on overhead and other fees by joining the first GPO for ketamine clinics and practitioners. There’s no cost to join and zero obligations. Sign up here!
Closing the Right to Try Gap
The legislation addresses a critical gap in existing federal law. While the 2018 Right to Try Act allows terminally ill patients to access unapproved treatments, the DEA has no pathway to authorize physicians to administer Schedule I substances. The Freedom to Heal Act would change that by amending the Controlled Substances Act.
Sen. Rand Paul, a physician himself, emphasized the practical nature of the reform. Current law leaves doctors with no legal way to administer investigational therapies under Schedule I, even when patients have exhausted all standard options.
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
Veterans at the Center
The bill carries special significance for military veterans. Thousands of former service members struggle with treatment resistant PTSD and depression. Many have traveled abroad to access psychedelic therapies unavailable in the United States.
Martin R. Steele, president of the Veteran Mental Health Leadership Coalition, called on Congress to act with urgency. Veterans should not have to leave the country they served to find potentially lifesaving treatments, he noted.
RELATED: A Veteran’s Guide to Getting Ketamine Therapy from the VA
Building on Previous Efforts
This legislation represents the third attempt by Booker and Paul to expand psychedelic access. Earlier versions sought to move breakthrough therapies to lower schedules entirely. The current bill takes a narrower approach, focusing specifically on physician authorization.
The FDA has already recognized the therapeutic potential of these substances. Both MDMA and psilocybin hold breakthrough therapy designations for serious mental health conditions. Clinical trials have shown promising results for treatment resistant depression and PTSD.
For patients who have tried everything else, this bill offers something powerful: hope.
